PARLIAMENT QUESTION: DEVELOPMENT OF INDIGENOUS ANTIBIOTICS

1. At a Glance

• Nafithromycin is India's first indigenously discovered antibiotic, developed by Wockhardt Ltd with partial public funding via BIRAC (DBT), targeting Community Acquired Bacterial Pneumonia (CABP) [S1][S2][S3].
• A novel macrolide (lactone ketolide, code WCK 4873), brand name "Miqnaf", marketed as a 400 mg tablet, 3-day once-daily regimen [S1][S2].
• Flagship case study for Antimicrobial Resistance (AMR) containment + Atmanirbhar Bharat in drug discovery — directly examinable under GS-III Sci-Tech and Health.

2. Why in the News

• 11 Feb 2026: Ministry of Science & Technology answered a Parliament Question stating CDSCO has issued marketing authorization for Nafithromycin 400 mg tablets to Wockhardt for adults (≥18 yrs) with CABP [S1].
• 20 Nov 2024: Union Minister Dr. Jitendra Singh soft-launched Nafithromycin as India's first indigenous antibiotic against drug-resistant respiratory infections [S3].

3. Background & Evolution

• 2010s onward: Wockhardt programme on novel anti-infectives (WCK 4873) initiated; ~14 years of R&D, ~₹500 crore investment [S3].
• Clinical trials: Phase II/III across US, Europe, India; Indian Phase-III part-supported by BIRAC [S1][S3].
• Nov 2024: Soft launch as India's first indigenous macrolide [S3].
• Feb 2026: Confirmed in Parliament — CDSCO marketing authorization granted [S1].
• Sits within wider AMR response: National Action Plan on AMR (NAP-AMR, 2017) and Schedule H1 of Drugs & Cosmetics Rules.

4. Core Static Facts

• Drug class: Novel macrolide / lactone ketolide [S1][S2].
• Indication: Community Acquired Bacterial Pneumonia (CABP) in adults ≥18 yrs [S1].
• Developer: Wockhardt Limited (Mumbai-based pharma) [S1].
• Funder (Phase-III India): BIRAC — Biotechnology Industry Research Assistance Council, a Section 8 not-for-profit PSE under Department of Biotechnology (DBT), Ministry of Science & Technology [S1].
• Regulator: Central Drugs Standard Control Organisation (CDSCO) under Ministry of Health & Family Welfare (Drugs & Cosmetics Act, 1940) [S1].
• Dosage form: Tablet 400 mg; 3-day once-daily oral regimen [S1][S2].
• Brand name: Miqnaf [S3].
• Claimed efficacy: ~10× more effective than current macrolide options; compared head-to-head with moxifloxacin in Phase-III [S2][S3].

5. Multi-Dimensional Analysis

Scientific / Technological - First Indian-origin new chemical entity (NCE) antibiotic — moves India up the value chain from generics manufacturing to original drug discovery [S3]. - Targets macrolide-resistant Streptococcus pneumoniae, a WHO-priority resistance phenotype [S2].

Health / Social - CABP disproportionately hits elderly, children, diabetics, cancer/immunocompromised patients — addresses an equity-relevant disease burden [S3]. - Shorter 3-day regimen improves adherence, reducing further resistance selection [S2].

Economic - ~₹500 crore, 14-year private R&D cycle de-risked by BIRAC grant — validates PPP model for drug discovery [S3]. - Reduces import dependence for novel antibiotics; strengthens Atmanirbhar Bharat in pharma.

Governance / Administrative - Demonstrates inter-ministerial coordination: DBT–BIRAC (funding) + CDSCO/MoHFW (regulation) + private industry (commercialisation) [S1]. - Linked instrument: ₹1 lakh crore RDI Initiative with a ₹2,000 crore BIRAC–RDI Fund announced 2026 to scale such projects [S4].

Global / Strategic - Aligns with WHO Global Action Plan on AMR (2015) and India's NAP-AMR; positions India as a contributor, not just consumer, of new antibiotics.

6. Recent Developments (12–18 months)

• 20 Nov 2024: Soft launch of Nafithromycin by Dr. Jitendra Singh [S3].
• 2024–25: Phase-III randomized double-blind trial vs. moxifloxacin completed [S2].
• 11 Feb 2026: PIB Parliament Q&A confirms CDSCO marketing nod [S1].
• 2026: Announcement of ₹2,000 crore BIRAC–RDI Fund under the ₹1 lakh crore RDI scheme to boost biotech R&D [S4].

7. Prelims Hooks

• Nafithromycin = India's first indigenously discovered antibiotic [S3].
• Developer: Wockhardt Ltd; brand: Miqnaf [S3].
• Drug class: Novel macrolide (lactone ketolide WCK 4873) [S1][S2].
• Indication: CABP in adults ≥18 years [S1].
• Strength: 400 mg tablet, once daily for 3 days [S1][S2].
• Phase-III India funder: BIRAC [S1].
• BIRAC is a Section 8 not-for-profit PSE under DBT, Ministry of Science & Technology [S1].
• Marketing authorization: CDSCO under MoHFW (Drugs & Cosmetics Act, 1940) [S1].
• Comparator drug in Phase-III: Moxifloxacin [S2].
• Investment: ~₹500 crore over ~14 years R&D [S3].
• Linked instrument: ₹2,000 crore BIRAC–RDI Fund under ₹1 lakh crore RDI Initiative [S4].
• Announcement minister: Dr. Jitendra Singh, MoS (IC) S&T, on 20 Nov 2024 [S3].

8. Mains Relevance

• GS-III: Science & Technology — indigenization & developing new technology; Issues relating to development & spread of new drugs; Health.
• GS-II: Issues relating to health, government policies and interventions.
• Plausible question stems: 1. "Indigenous drug discovery is the missing pillar of India's pharma success story." Examine in light of Nafithromycin's development. 2. Discuss how Public-Sector instruments like BIRAC are de-risking private R&D in critical health technologies. 3. Critically evaluate India's response to Antimicrobial Resistance (AMR), with reference to recent indigenous antibiotic development.

9. Related Topics to Study Next

• National Action Plan on AMR (2017) — policy umbrella for antibiotic stewardship.
• BIRAC & DBT schemes (BIG, SBIRI, BIPP) — startup/R&D funding ecosystem.
• CDSCO & New Drugs and Clinical Trials Rules, 2019 — regulatory pathway.
• Schedule H1 of Drugs & Cosmetics Rules — restricted antibiotic sale.
• PLI Scheme for Pharmaceuticals & Bulk Drugs — manufacturing self-reliance.
• Anusandhan National Research Foundation (ANRF) Act, 2023 — R&D financing architecture.
• WHO Priority Pathogens List & Global AMR Action Plan — international context.
• One Health approach — human-animal-environment AMR linkage.

10. Common Errors / Trap Areas

• BIRAC is under DBT (Ministry of S&T), NOT MoHFW — easy mix-up [S1].
• CDSCO sits under MoHFW, not DBT — separate the funder vs. regulator.
• Nafithromycin treats CABP (bacterial pneumonia), not TB or any viral disease [S1].
• It is a macrolide, not a fluoroquinolone; moxifloxacin was only the trial comparator [S2].
• "First indigenously discovered" antibiotic ≠ first antibiotic manufactured in India (India makes generics for decades) [S3].

11. Sources

• [S1] PARLIAMENT QUESTION: Development of Indigenous Antibiotics, PIB, 11 Feb 2026 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2226280 — (tier 1)
• [S2] Nafithromycin Phase-III trial vs moxifloxacin (NCBI/PMC, referenced via PIB search) — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12494923/ — (tier 2 supporting)
• [S3] Dr. Jitendra Singh announces soft launch of India's First Indigenous Antibiotic Nafithromycin, PIB, Nov 2024 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2075174 — (tier 1)
• [S4] ₹2,000 Crore BIRAC–RDI Fund under ₹1 Lakh Crore RDI Initiative, PIB, 2026 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2227506 — (tier 1)